Please login to the form below

Not currently logged in

Daiichi sets up new vaccine research unit

Japanese pharma company establishes new research facility at its Kasai R&D Center in Tokyo

Daiichi Sankyo has set up a new vaccine research unit in Tokyo as part of a drive to expand its R&D in infectious diseases.

The unit will be located in the Japanese pharma company's Kasai R&D Center at Edogawa-ku, Tokyo and focus on making pharmacological assessments for vaccines, including the immunogenicity of candidate antigens and their ability to fend off infection.

Daiichi has been expanding its vaccine business of late, and in April this year set up an exploratory vaccine research unit within the Osaka-based National Institute of Biomedical Innovation.

This unit is already performing exploratory vaccine research and "continuously reinforcing and expanding R&D for new adjuvants," the company said.

It added: "Now, with two vaccine research units and partnerships with organisations inside and outside of the Group, Daiichi Sankyo is poised to fully realise its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them."

Daiichi's domestic subsidiary Kitasato Daiichi Sankyo Vaccine Co. was recently forced to delay supplying its influenza HA vaccine and vaccine syringe to the Japanese market after some batches failed to meet quality standards.

Shipments of the vaccine resumed at the end of last month, but only half of the 4.8 million dose supply met Daiichi's quality specification and the company aims to ramp up production in order to supply an additional 1.2 million doses from the beginning of January 2012.

1st November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...